Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
Holding PSNL?
Track your performance easily
PSNL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.12 - $7.20
Previous CloseN/A
Volume738.16K
Average Volume (3M)1.41M
Market Cap
$434.64M
Enterprise Value$229.96M
Total Cash (Recent Filing)$22.62M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Feb 20, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding71,019,875
10 Day Avg. Volume1,298,287
30 Day Avg. Volume1,410,320
Standard Deviation0.34
R-Squared0.08
Alpha0.00683
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.94
Price to Cash Flow (P/CF)-17.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue2.63
Enterprise Value/Gross Profit12.63
Enterprise Value/Ebitda-2.79
Forecast
1Y Price Target
$7.54Price Target Upside38.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Personalis News
Bulls Say, Bears Say
Bulls Say
Financial PerformancePersonalis reported preliminary 4Q24 revenues of approximately $16.8M, ahead of our estimate of $15.4M and consensus of $15.5M.
Revenue Growth PotentialPersonalis has a path to achieve 20-30%+ revenue growth from its biopharma business over the next couple of years.
Strategic PartnershipsThe extension of the Moderna agreement and the $50M strategic investment by Merck provided additional validation of the Company’s efforts.
Bears Say
Client RelationshipRevenues from the company’s client, Natera, may not be meaningful in 2025 as the relationship winds down.
Price TargetThe 12-month price target is lowered to $8.00 per share from the previous target of $11.00.
Revenue DeclineA 21% YoY decline in the VA MVP revenues was noted, partially offsetting the higher biopharma revenues.
---
Ownership Overview
25.51% Insiders
5.16% Mutual Funds
0.07% Other Institutional Investors
56.75% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PSNL FAQ
What was Personalis Inc’s price range in the past 12 months?
Personalis Inc lowest stock price was $1.12 and its highest was $7.20 in the past 12 months.
What is Personalis Inc’s market cap?
Personalis Inc’s market cap is $434.64M.
When is Personalis Inc’s upcoming earnings report date?
Personalis Inc’s upcoming earnings report date is Feb 20, 2025 which is in 21 days.
How were Personalis Inc’s earnings last quarter?
Personalis Inc released its earnings results on Nov 06, 2024. The company reported -$0.64 earnings per share for the quarter, missing the consensus estimate of -$0.35 by -$0.29.
Is Personalis Inc overvalued?
According to Wall Street analysts Personalis Inc’s price is currently Undervalued.
Does Personalis Inc pay dividends?
Personalis Inc does not currently pay dividends.
What is Personalis Inc’s EPS estimate?
Personalis Inc’s EPS estimate is -0.28.
How many shares outstanding does Personalis Inc have?
Personalis Inc has 71,019,875 shares outstanding.
What happened to Personalis Inc’s price movement after its last earnings report?
Personalis Inc reported an EPS of -$0.64 in its last earnings report, missing expectations of -$0.35. Following the earnings report the stock price went down -22.581%.
Which hedge fund is a major shareholder of Personalis Inc?
Currently, no hedge funds are holding shares in PSNL
---
Personalis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.54 (38.60% Upside)
$7.54 (38.60% Upside)
Hedge Fund Trend
Increased
By 744.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $204.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
289.80%
12-Months-Change
Fundamentals
Return on Equity
-57.52%
Trailing 12-Months
Asset Growth
5.85%
Trailing 12-Months
Company Description
Personalis Inc
Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.
---
PSNL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call indicates strong revenue growth and successful capital raising, which are positive signs for Personalis' future. However, the net loss increase and expected revenue decline in the next quarter present challenges. Overall, the positive aspects slightly outweigh the negatives, as the company seems well-positioned for future growth, particularly in the MRD market.Read More>---
PSNL Stock 12 Month Forecast
Average Price Target
$7.54
▲(38.60% Upside)
Technical Analysis
Exact Sciences
―
Illumina
―
Rocket Pharmaceuticals
―
Fulgent Genetics
―
Guardant Health
―
Best Analysts Covering PSNL
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+93.20%
reiterated a buy rating 24 days ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +93.20% per trade.
---